Mark H. Skolnick
Keine laufenden Positionen mehr
Karriereverlauf von Mark H. Skolnick
Ehemalige bekannte Positionen von Mark H. Skolnick
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Direktor/Vorstandsmitglied | - | - |
MYRIAD GENETICS, INC. | Direktor/Vorstandsmitglied | 01.05.1991 | 03.02.2010 |
Technik-/Wissenschafts-/F&E-Leiter | 01.05.1991 | - | |
Gründer | 01.05.1991 | - |
Ausbildung von Mark H. Skolnick
Stanford University | Doctorate Degree |
University of California, Berkeley | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Börse
- Insiders
- Mark H. Skolnick
- Erfahrung